The study design involved starting patients on tirzepatide (sold under the brand names Mounjaro and Zepbound), a once-weekly injectable medication that treats type 2 diabetes, weight loss, and obstructive sleep apnea
GHK-Cu activates the Wnt/beta-catenin pathway that drives the anagen (growth) phase of the hair cycle, stimulates VEGF and hepatocyte growth factor for follicle health, and has been shown in clinical research to increase follicle size and density with sustained use
Legal Disclaimer: This product and associated materials have not been evaluated by the FDA
Dosage and Administration : Proper dosing is critical to achieving optimal results while minimizing potential side effects
Fat oxidation rates, NAD+ levels, and insulin sensitivity improvements gained during the cycle will decline unless maintained through continued caloric deficit and training stimulus
The right pick depends on whether you value an intensive program or fast, focused medication access